MSF wants to buy groundbreaking HIV prevention drug. Why won’t Gilead sell?

MSF sent an open letter urging Gilead to immediately sell lenacapavir for HIV prevention and requested a follow-up meeting by 13 April. Global need is large: ~1.3m new HIV infections per year, while available supply via the Global Fund is capped at enough doses for up to 2m people over 3 years and only a handful of the 18 eligible countries have received doses. MSF says Gilead has refused direct sales to its programmes and that current eligibility and supply constraints leave millions at high risk.

Analysis

This is less about a single NGO complaint and more about signaling around access governance that can materially change procurement pathways in low- and middle-income markets. If donors and national programs perceive a manufacturer as constraining access, they accelerate alternatives: pooled tenders, compulsory licensing, or pivoting to other long-acting PrEP suppliers — any of which would compress future realized price and mix for the incumbent over a 12–36 month horizon.

Operationally, constrained direct sales to humanitarian actors amplifies stress on third-party channels (Global Fund, PEPFAR) and concentrates negotiation leverage in donors who can demand volume discounts and tighter terms; that raises the odds of margin erosion even as unit volumes rise. Meanwhile, fill-finish and sterile injectables capacity becomes the choke point — increased tendering for alternatives benefits CDMOs and manufacturers with commercial-scale LA injection capability.

Market reaction will likely be a muted near-term reputational wobble but a more meaningful re-rating if (a) coordinated procurement shifts appear within 3–9 months or (b) governments threaten compulsory licensing within 12–24 months. The right way to express this in portfolios is asymmetric, option-focused exposure to policy/regulatory downside while owning beneficiaries of redistributed demand (competitors and CDMOs) rather than naked large-cap short positions.

Key Decisions for Investors

• Buy GILD 6–9 month 10% OTM put options sized to risk 1–2% of portfolio: asymmetric hedge against a 15–30% downside if procurement shifts or policy actions accelerate; limit time-decay by targeting 6–9 month expiries.
• Pair trade (6–12 months): Short GILD (cash or 1–2% notional) / Long GSK (equal dollar notional) to capture potential share shift in long‑acting PrEP procurement; target 8–15% relative outperformance, stop-loss at 6% adverse move.
• Long select CDMOs (e.g., CTLT) 12–24 months: buy shares or call spreads to play increased demand for sterile injectable manufacturing capacity; risk/reward ~1:3 if contracts and tendering accelerate within 12 months.
• If cost of protection is high, implement a structured hedge: buy 6–9 month GILD puts and sell farther-dated or deeper OTM puts to finance premium — limiting downside while keeping asymmetric payoff if regulatory/ procurement catalysts materialize.